Dr. Michael D. Amos is the Biosciences Advisor to the Director of the Chemical Science and Technology Laboratory, National Institute of Standards and Technology (NIST), Technology Administration, U.S. Department of Commerce. Dr. Amos received his B.S. degree in General Sciences from Virginia Commonwealth University, Richmond, Virginia and his Ph.D. in Basic Medical Sciences from the University of South Alabama, College of Medicine in Mobile, Alabama. His graduate area of emphasis was in microbiology and immunology and his thesis research was in regulation of the immune system. From there, he furthered his training at the University of Alabama at Birmingham, College of Medicine as a postdoctoral fellow in the Departments of Microbiology and Rheumatology, studying the molecular immunology of rheumatoid arthritis. He spent several years working in a hospital emergency department while completing his undergraduate degree and has held various industry research, marketing and business development positions in the fields of biopharmaceuticals, neutriceuticals, drug delivery, transgenics, immunodiagnostics, molecular biology and molecular pathology. He was also a founder of two biotechnology companies. Dr. Amos joined NIST in 2002 as a Program Manager and Biologist in the Chemistry and Life Sciences Office of the Advanced Technology Program (ATP), an extramural funding arm of NIST, established to accelerate private sector high-risk, high-reward technology development projects. At ATP, he managed projects on stem cells, nanotechnology, immunotherapeutics, cancer vaccines, neurobiology, protein therapeutics, drug discovery, gene therapy, metabolic engineering, and medical devices. Dr. Amos is a leader in the field of autoimmune immunodiagnostics and serves on the Autoimmune Disease Coordinating Committee of the National Institutes of Health. Mike joined CSTL in 2006, and serves as liaison to industry, academia and other government agencies in the bioscience and health care areas.